Title of article
Crystal structure of a 1:1 co-crystal of the anticancer drug gefitinib with azelaic acid
Author/Authors
George, Christy P. Physical and Materials Chemistry Division - CSIR-National Chemical Laboratory, India , Sangtani, Ekta Physical and Materials Chemistry Division - CSIR-National Chemical Laboratory, India , Gonnade, Rajesh G. Physical and Materials Chemistry Division - CSIR-National Chemical Laboratory, India
Pages
15
From page
1
To page
15
Abstract
In the title co-crystal, C22H24ClFN4O3·C9H16O4, gefitinib (GTB; systematic name: quinazolin-4-amine) co-crystallizes with azelaic acid (AA; systematic name: nonanedioic acid). The co-crystal has the monoclinic P21/n centrosymmetric space group, containing one molecule each of GTB and AA in the asymmetric unit. A structure overlay of the GTB molecule in the co-crystal with that of its most stable polymorph revealed a significant difference in the conformation of the morpholine moiety. The significant deviation in the conformation of one of the acidic groups of azelaic acid from its usual linear chain structure could be due to the encapsulation of one acidic group in the pocket formed between the two pincers of GTB namely, the morpholine and phenyl moieties. Both GTB and AA molecules form N—H⋯O, O—H⋯N, C—H⋯O hydrogen bonds with C—H⋯F close contacts along with off-stacked aromatic π–π interactions between the GTB molecules.
Keywords
anticancer , azelaic acid , co-crystal , crystal structure , gefitinib , hydrogen bond , π–π interactions
Journal title
Acta Crystallographica Section E: Crystallographic Communications
Serial Year
2020
Record number
2623589
Link To Document